Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer

A randomized trial showed noninferiority of stereotactic body radiotherapy to conventionally or moderately hypofractionated radiotherapy in preventing biochemical recurrence in selected men with localized prostate cancer.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology